Business
Chai Discovery Announces Collaboration with Eli Lilly and Company to Accelerate Biologics Discovery
SAN FRANCISCO, January 09, 2026--Chai Discovery, the AI company building a computer-aided design suite for molecules, announces Eli Lilly and Company collaboration.
About this update from Eli Lilly And Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/a75bf0b588e00f006480d6e3efda88d9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WQEcKIdksl3a7bs7z1LjiA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a75bf0b588e00f006480d6e3efda88d9","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/sou20chy4.tZ_DtmvaCNlw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/a75bf0b588e00f006480d6e3efda88d9","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Chai Discovery’s AI platform, including purpose-built custom models, will be deployed to accelerate the discovery of next-generation therapeutics ","length":145,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, January 09, 2026--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with Eli Lilly and Company (Lilly) to accelerate biologics discovery using artificial intelligence.","length":266,"tagName":"p"},{"type":"text","content":"Under the collaboration, Lilly will deploy Chai’s frontier AI platform to design novel biologic therapeutics for multiple targets. In addition, Chai will develop a purpose-built AI model, exclusively for use by Lilly, trained on large-scale proprietary Lilly data and tailored to Lilly’s discovery workflows. The collaboration follows a period during which a set of Chai’s model designs were evaluated by Lilly.","length":411,"tagName":"p"},{"type":"text","content":""Our collaboration with Lilly brings together the strengths of both organizations, combining Chai’s expertise in building frontier models with Lilly’s ability to deploy technology to accelerate their efforts to make a positive impact on the lives of patients. Beyond providing access to our core models, training custom models trained on Lilly’s data presents the opportunity to expand the boundaries of AI-enabled early-stage drug discovery and development," said Josh Meier, CEO of Chai Discovery.","length":509,"tagName":"p"},{"type":"text","content":"Chai-2 is the first zero-shot antibody design platform to achieve doub...